This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Treatment, CSF, and Neuroendocrine Responses

Michael I. Levy, MD; Bonnie M. Davis, MD; Richard C. Mohs, PhD; Kenneth S. Kendler, MD; Alexander A. Mathe, MD, PhD; Gaston Trigos, MD; Thomas B. Horvath, MD; Kenneth L. Davis, MD

Arch Gen Psychiatry. 1984;41(5):520-524.

Abstract
• Previous studies have variably reported the efficacy of apomorphine in treatment of schizophrenia and tardive dyskinesia. Stimulation of dopamine neuron autoreceptors is the presumed mode of action. Low-dose apomorphine (0.75 mg subcutaneously) and placebo were administered to 25 male schizophrenics to evaluate the drug's effect on psychotic and tardive dyskinetic symptoms. No significant improvement or deterioration was seen. Concomitant measurements of plasma prolactin and growth hormone levels and CSF homovanillic acid level indicated that the dose used was centrally active. These results indicate that an active though nonsedating dose of apomorphine does not ameliorate symptoms of schizophrenia or tardive dyskinesia.

Author Affiliations
From the Schizophrenia Biological Research Center, and the Medical Research Services, Bronx (NY) Veterans Administration Medical Center, and the Department of Psychiatry, Mt Sinai School of Medicine, New York (Drs Levy, Davis, Mohs, Kendler, Mathe, Horvath, and Davis); and the Montrose (NY) Veterans Administration Hospital (Dr Trigos). Dr Levy is currently with Nyack (NY) Hospital; Dr Kendler is now with the Medical College of Virginia, Richmond; Dr Mathe is now with the Karolinska Institute, Stockholm.

Footnotes
Accepted for publication Aug 10, 1983.

Reprint requests to Department of Psychiatry, Veterans Administration Medical Center, 130 W Kingsbridge Rd, Bronx, NY 10468 (Dr Davis).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Dopamine Agonist Treatment of Schizophrenia With N-Propylnorapomorphine
Tamminga et al.
Arch Gen Psychiatry 1986;43:398-402.
ABSTRACT  

Apomorphine's Antipsychotic Activity
Schaffer et al.
Arch Gen Psychiatry 1985;42:927-927.
ABSTRACT  

Apomorphine's Antipsychotic Activity-Reply
Davis et al.
Arch Gen Psychiatry 1985;42:927-928.
ABSTRACT  

Evaluating Prolactin Response to Dopamine Agonists in Schizophrenia: Methodological Problems
Davis et al.
Arch Gen Psychiatry 1985;42:259-264.
ABSTRACT